WHATNEXT partner website Patient Worthy reported on the approval of erdafitinib (marketed as Balversa) as a treatment for urothelial carcinoma that is metastatic or locally advanced. This is an update to the label for the drug, which was previously only approved for use after a course of platinum-based chemotherapy. Author Jessica Lynn reports:
Now, with full approval, Balversa is indicated for individuals with susceptible FGFR3 alterations whose condition has progressed following at least one prior line of systemic treatment. The approval follows data from the Phase 3 THOR study. Approximately 630 participants enrolled. Balversa showed promise over the existing standard-of-care for urothelial carcinoma; the therapy improved survival rate by a median of 4 months and reduced mortality risk by 36% when compared to chemotherapy.
Check out the full story here.
Editor’s Note: Get Involved
Cancer doesn’t discriminate. Patient Worthy and its partners are interested in amplifying the voices of those from all identities and backgrounds. If you have a cancer journey to share, reach out here to learn more about how your voice can help spread awareness and inspire individuals from all walks of life.
FDA Treatment Approvals urothelial carcinoma
Last modified: March 6, 2024
